PAR and the Possible Sales Projection, page-23

Ceviche, your analysis and comments only enhance our beaut threads. Thanks.

I totally agree with you except I want to add one thing. You did comment that you feel $3000 or so revenue might be a bit of a stretch.
Ordinarily I would wholeheartedly agree with you, in fact I base most of my personal calcs on even lower revenue (Usually I take just $2000). But honestly, we get through the durability study and it shows at least 50% patients experience the good effects of iPPS for more than 9 months (12 ideally), I'm telling you even $3000 will be at the lower end of what we will be able to charge.

How? Why?

There is no need in the case of many patients to spend a single $ more. You and I both have read cases on here where the patient has not had even a booster for 25 months and are still, to this day experiencing little to NO pain.

We know our CEO has a booster once a year and has staved off surgery for 8 years. You tell me what payer will not pay for us if they are effectively not having to pay for surgery (upwards of $30 K), hospital stays and also the very expensive rehab programs?

Long term views expressed here. DYOR What a drug.